Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of … – GlobeNewswire (press release)
|
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of …
GlobeNewswire (press release) ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR technology, and its collaborator, Novartis … |
